Skip to main content

Table 1 Secondary Biomarker End Points

From: Study protocol: rationale and design of the community-based prospective cohort study of kidney function and diabetes in rural New Mexico, the COMPASS study

Concentration of β2M versus eGFR and markers of inflammation (high sensitivity C-reactive protein or hsCRP) in all evaluable participants
Laboratory markers of glycemic control (HgbA1C), and insulin sensitivity (HOMeostatic model Assessment (HOMA) for assessing beta-cell function and Insulin Resistance or HOMA-IR, C-peptide index) versus eGFR in all screened participants
Relation between emerging renal filtration markers (β2M and CysC) in participants with CKD
Relation of β2M, CysC and insulin sensitivity at each time point to rate of decline of the eGFR (ΔeGFR)
Relation between inflammation (hsCRP), eGFR and ΔeGFR
Relation of laboratory markers of CKD (anemia, calcium, phosphorus, parathyroid hormone, vitamin D), abnormal serum electrolytes, osmoregulation and urinary biomarkers (hematuria, albuminuria, proteinuria, urine electrolytes) to eGFR and ΔeGFR
Relation of progressive CKD (ΔeGFR > 3 ml/min/1.73m2 per year) status in the community to personal, medical and family history risk factors